ATE74766T1 - Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit. - Google Patents
Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit.Info
- Publication number
- ATE74766T1 ATE74766T1 AT84306027T AT84306027T ATE74766T1 AT E74766 T1 ATE74766 T1 AT E74766T1 AT 84306027 T AT84306027 T AT 84306027T AT 84306027 T AT84306027 T AT 84306027T AT E74766 T1 ATE74766 T1 AT E74766T1
- Authority
- AT
- Austria
- Prior art keywords
- life
- serum half
- therapeutic agents
- antibody compositions
- preparing antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08323428A GB2148299B (en) | 1983-09-01 | 1983-09-01 | Antibody compositions of therapeutic agents having an extended serum half-life |
| EP84306027A EP0136835B1 (de) | 1983-09-01 | 1984-09-03 | Verfahren zur Herstellung von Antikörperzusammensetzungen von therapeutischen Mitteln mit verlängerter Serumhalbwertzeit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE74766T1 true ATE74766T1 (de) | 1992-05-15 |
Family
ID=10548161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT84306027T ATE74766T1 (de) | 1983-09-01 | 1984-09-03 | Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5055289A (de) |
| EP (1) | EP0136835B1 (de) |
| JP (1) | JPH0717519B2 (de) |
| AT (1) | ATE74766T1 (de) |
| AU (1) | AU593208B2 (de) |
| CA (1) | CA1249222A (de) |
| DE (1) | DE3485649D1 (de) |
| DK (1) | DK191985A (de) |
| FI (1) | FI85441C (de) |
| GB (1) | GB2148299B (de) |
| WO (1) | WO1985000974A1 (de) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453269A (en) * | 1986-04-14 | 1995-09-26 | The General Hospital Corporation | Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use |
| US4894227A (en) * | 1986-08-01 | 1990-01-16 | Cetus Corporation | Composition of immunotoxins with interleukin-2 |
| FR2604092B1 (fr) * | 1986-09-19 | 1990-04-13 | Immunotech Sa | Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo |
| US5009888A (en) * | 1987-04-13 | 1991-04-23 | Genzyme Corporation | Therapeutic enzyme-antibody complexes |
| DE3889783T2 (de) * | 1987-07-07 | 1994-09-08 | Hybrisens Ltd | Verwendung von Antikörper-Antigen-Wechselwirkung zum Schutz oder Modulation der biologischen Aktivität. |
| EP0415929A1 (de) * | 1988-01-15 | 1991-03-13 | Centocor, Inc. | Hetero-unterbindende antikörper und ihre therapeutische benutzung |
| US5322678A (en) * | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
| US5582862A (en) | 1988-04-04 | 1996-12-10 | General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
| US5372812A (en) * | 1988-04-04 | 1994-12-13 | The General Hospital Corporation | Composition and method for acceleration of clot lysis |
| US5225540A (en) * | 1988-04-26 | 1993-07-06 | Du Pont Merck Pharmaceutical Company | Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life |
| GB8813527D0 (en) * | 1988-06-08 | 1988-07-13 | Glennie M J | Bispecific antibodies |
| US5686579A (en) * | 1988-06-21 | 1997-11-11 | Hybrisens, Ltd. | Use of antibody/antigen interactions to protect biologically active proteins and peptides |
| DE68919361T2 (de) * | 1988-06-21 | 1995-05-24 | Genentech Inc | Therapeutische zusammensetzungen für die behandlung von myocard-infarkten. |
| IE62463B1 (en) * | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
| US5763573A (en) * | 1988-08-10 | 1998-06-09 | Chiron Corporation | GTPase activating protein fragments |
| US5760203A (en) * | 1988-08-10 | 1998-06-02 | Chiron Corporation | Gap gene sequences |
| US5609869A (en) * | 1988-08-19 | 1997-03-11 | The General Hospital Corporation | Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use |
| US5811265A (en) * | 1988-08-19 | 1998-09-22 | The General Hospital Corporation | Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use |
| KR900005995A (ko) * | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| IE63847B1 (en) * | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| SE509359C2 (sv) * | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
| US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| DE69102265T2 (de) * | 1990-02-06 | 1994-10-13 | Takeda Chemical Industries, Ltd., Osaka | Immunkomplexe. |
| US5506134A (en) * | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| NZ263102A (en) * | 1993-03-19 | 1997-05-26 | Immunex Corp | Pharmaceutical compositions comprising a ligand protein such as interleukin-4 and a soluble receptor protein that binds thereto |
| US20030017147A1 (en) * | 1996-09-20 | 2003-01-23 | Guy L Reed | Composition and method for enhancing fibrinolysis |
| US6313089B1 (en) | 1997-08-20 | 2001-11-06 | Duke University | Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use |
| JP2001518449A (ja) * | 1997-09-30 | 2001-10-16 | デューク・ユニバーシティー | アポリポタンパク質ｅ／成長因子複合体およびその使用法 |
| EP1351707B9 (de) * | 2001-01-09 | 2012-01-25 | Baylor Research Institute | Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays |
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| WO2003007889A2 (en) | 2001-07-17 | 2003-01-30 | Research Development Foundation | Therapeutic agents comprising pro-apoptotic proteins |
| EP1443963B1 (de) * | 2001-10-22 | 2014-05-21 | The Scripps Research Institute | Antikörper-targeting-verbindungen |
| AU2002337954C1 (en) * | 2001-10-22 | 2008-10-23 | The Scripps Research Institute | Integrin targeting compounds |
| US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
| US20060002935A1 (en) * | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| US20070298041A1 (en) * | 2002-06-28 | 2007-12-27 | Tomlinson Ian M | Ligands That Enhance Endogenous Compounds |
| US20080008713A1 (en) * | 2002-06-28 | 2008-01-10 | Domantis Limited | Single domain antibodies against tnfr1 and methods of use therefor |
| EP1900753B1 (de) | 2002-11-08 | 2017-08-09 | Ablynx N.V. | Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür |
| US20040175359A1 (en) * | 2002-11-12 | 2004-09-09 | Desjarlais John Rudolph | Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity |
| EP1426382A1 (de) * | 2002-12-06 | 2004-06-09 | Aventis Behring GmbH | Antivirales menschliches Serum Albumin |
| US20070202099A1 (en) * | 2004-03-30 | 2007-08-30 | Hiroshi Inooka | Antibody Drug |
| CN101056654A (zh) * | 2004-10-07 | 2007-10-17 | 苏黎士大学 | 用于预防和治疗银屑病的i型干扰素阻断剂 |
| MX2007006593A (es) * | 2004-12-02 | 2008-03-04 | Domantis Ltd | Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos. |
| GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| US7888481B2 (en) * | 2005-02-10 | 2011-02-15 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| CN101155831B (zh) * | 2005-02-10 | 2015-08-19 | 贝勒研究院 | 抗干扰素α单克隆抗体及其使用方法 |
| JP2009519011A (ja) * | 2005-12-01 | 2009-05-14 | ドマンティス リミテッド | インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット |
| EA200801166A1 (ru) * | 2005-12-01 | 2008-12-30 | Домантис Лимитед | Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| CA2688433A1 (en) * | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
| US7625555B2 (en) * | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
| CN102083859B (zh) | 2008-05-07 | 2014-09-17 | 阿哥斯医疗公司 | 人源化抗人干扰素-α抗体 |
| EP3721880B1 (de) | 2010-09-01 | 2022-02-02 | Thomas Jefferson University | Zusammensetzungen und verfahren zur muskelreparatur und -regeneration |
| EP2537933A1 (de) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine |
| EP3559049B1 (de) | 2011-10-28 | 2025-06-11 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptidkonstrukte und anwendungen davon |
| US11401312B2 (en) | 2013-04-19 | 2022-08-02 | Cytune Pharma | Cytokine derived treatment with reduced vascular leak syndrome |
| BR112015027313A2 (pt) | 2013-04-29 | 2017-09-26 | Teva Pharmaceuticals Australia Pty Ltd | anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| WO2015077491A1 (en) * | 2013-11-20 | 2015-05-28 | Regeneron Pharmaceuticals, Inc. | Aplnr modulators and uses thereof |
| EP2915569A1 (de) | 2014-03-03 | 2015-09-09 | Cytune Pharma | Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| US10544199B2 (en) | 2014-10-29 | 2020-01-28 | Teva Pharmaceuticals Australia Pty Ltd | Interferon alpha 2B variants |
| JP2019131471A (ja) * | 2016-05-27 | 2019-08-08 | 国立大学法人 東京大学 | 抗ＴＧＦ−ｂｅｔａ３抗体およびその使用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1509707A (en) * | 1974-09-20 | 1978-05-04 | Searle & Co | Immunological compounds |
| US4195017A (en) * | 1975-02-25 | 1980-03-25 | Samuel Bogoch | Malignin, derived from brain tumor cells, complexes and polypeptides thereof |
| IL47372A (en) * | 1975-05-27 | 1979-10-31 | Yeda Res & Dev | Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same |
| US4263279A (en) * | 1975-08-19 | 1981-04-21 | Yeda Research & Development Co. Ltd | Pharmaceutically active compositions containing adriamycin and daunomycin |
| GB1564666A (en) * | 1978-05-31 | 1980-04-10 | Ng Mun Hon | Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof |
| FR2437213A1 (fr) * | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| JPS5616417A (en) * | 1979-07-19 | 1981-02-17 | Teijin Ltd | Antitumor protein complex and its preparation |
| JPS5686121A (en) * | 1979-12-14 | 1981-07-13 | Teijin Ltd | Antitumor proten complex and its preparation |
| US4423147A (en) * | 1980-04-11 | 1983-12-27 | Secher David S | Monoclonal antibody to interferon-α |
| EP0044167A3 (de) * | 1980-07-14 | 1982-04-21 | The Regents Of The University Of California | Durch einen Antikörper gerichtetes zytotoxisches Mittel |
| US4359457A (en) * | 1980-09-30 | 1982-11-16 | Neville Jr David M | Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant |
| FI820020L (fi) * | 1981-01-12 | 1982-07-13 | Lilly Industries Ltd | Immunoglobulinkonjugater |
| FR2504010B1 (fr) * | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| GB2098219A (en) * | 1981-05-08 | 1982-11-17 | Erba Farmitalia | Daunorubicin-protein conjugates |
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| ES521370A0 (es) * | 1982-04-12 | 1985-04-16 | Hybritech Inc | Un procedimiento para obtener un polidoma. |
| US4520226A (en) * | 1982-07-19 | 1985-05-28 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates |
| CA1259923A (en) * | 1983-08-17 | 1989-09-26 | Roger Aston | Physiologically active compositions |
-
1983
- 1983-09-01 GB GB08323428A patent/GB2148299B/en not_active Expired
-
1984
- 1984-08-31 WO PCT/US1984/001389 patent/WO1985000974A1/en not_active Ceased
- 1984-08-31 AU AU33935/84A patent/AU593208B2/en not_active Ceased
- 1984-08-31 JP JP59503388A patent/JPH0717519B2/ja not_active Expired - Lifetime
- 1984-09-03 DE DE8484306027T patent/DE3485649D1/de not_active Expired - Fee Related
- 1984-09-03 AT AT84306027T patent/ATE74766T1/de not_active IP Right Cessation
- 1984-09-03 EP EP84306027A patent/EP0136835B1/de not_active Expired - Lifetime
- 1984-09-04 CA CA000462348A patent/CA1249222A/en not_active Expired
-
1985
- 1985-04-25 FI FI851635A patent/FI85441C/fi not_active IP Right Cessation
- 1985-04-29 DK DK191985A patent/DK191985A/da not_active Application Discontinuation
-
1988
- 1988-08-19 US US07/234,224 patent/US5055289A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60502104A (ja) | 1985-12-05 |
| AU593208B2 (en) | 1990-02-08 |
| EP0136835A2 (de) | 1985-04-10 |
| FI85441C (fi) | 1992-04-27 |
| JPH0717519B2 (ja) | 1995-03-01 |
| EP0136835A3 (en) | 1986-10-08 |
| DK191985D0 (da) | 1985-04-29 |
| WO1985000974A1 (en) | 1985-03-14 |
| GB8323428D0 (en) | 1983-10-05 |
| DE3485649D1 (de) | 1992-05-21 |
| FI851635A0 (fi) | 1985-04-25 |
| FI85441B (fi) | 1992-01-15 |
| US5055289A (en) | 1991-10-08 |
| FI851635L (fi) | 1985-04-25 |
| GB2148299B (en) | 1988-01-06 |
| GB2148299A (en) | 1985-05-30 |
| CA1249222A (en) | 1989-01-24 |
| EP0136835B1 (de) | 1992-04-15 |
| AU3393584A (en) | 1985-03-29 |
| DK191985A (da) | 1985-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE74766T1 (de) | Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit. | |
| ATE160583T1 (de) | Steigerungsverfahren der transmembranförderung von exogenen molekülen | |
| ATE16567T1 (de) | Intravenoes injektierbares globulin aus immunserum und verfahren zu seiner herstellung. | |
| ATE91901T1 (de) | Vehikel zur verabreichung von interferon. | |
| DD129788A5 (de) | Verfahren zur herstellung von 3',3'',5',5''-tetrachlorphenol-3,4,5,6-tetrabromsulfophthalein bzw.3',3''-dibrom-5',5''-dichlorphenol-3,4,5,6-tetrachlorsulfophthalein | |
| ATE866T1 (de) | Immunserumglobulin (isg)-praeparate und verfahren zu ihrer herstellung. | |
| NO149309C (no) | Anvendelse av vannloeselige anioniske polymerisater som additiv i dypborsementer | |
| FI860285A0 (fi) | 6-tioxantinderivat. | |
| AT356265B (de) | Verfahren zur herstellung von nicht mehr antikomplementaer wirksamen nativ-human- -immunglobulin zur intravenoesen verabreichung mit natuerlicher halbwertszeit | |
| DE69111464D1 (de) | Reduktion von benzol in benzin. | |
| BG42677A3 (en) | Method for preparing of 6- alpha- methylcorticoides | |
| ATE55620T1 (de) | Verfahren zur herstellung von interferon. | |
| DE3671452D1 (de) | Technetium-aren-komplexe und verfahren. | |
| GB1490290A (en) | Preparation of penicillanic acid derivatives | |
| AT344885B (de) | Verfahren zur herstellung von 18-arabinosyl-2-n-butyl-3,7,11,15,19,21,23,25,27,37-dekahydroxy-4,16,32,34,36-pentamethyl-tetrakonta-16,32-dien-35-o-lacton-40-guanidiniumsulfat(debrycin) enthaltenden pharmazeutischen praeparaten | |
| GB1520114A (en) | Hardening fixer for use in the processing of photographic elements | |
| NL7603461A (nl) | D-homosteroiden en werkwijze voor de bereiding daarvan. | |
| GB1530848A (en) | 2-(phenylalkylhydrazono)-propionic acid derivatives | |
| GB1136039A (en) | Improvements relating to immunosuppressive agents | |
| DD128525A5 (de) | Verfahren zur herstellung von 1,2,3,4-tetrahydro-4-oxo-(oder-oxy-)-1-naphthylharnstoffen | |
| ES374949A2 (es) | Un procedimiento para la preparacion de beta-naftilacetami-dina. | |
| IT1034682B (it) | Procedimento per produrre proteine di alta qualita utilizzando rifiuti contementi albumine. | |
| ES191162U (es) | Juguete de composicion. | |
| AT191552B (de) | Verfahren zur Herstellung von 8[2',6',6'-Trimethylcyclohexen-(1')-yl]-2,6-dimethyloctatrien-(2,4,6)-al-(1) | |
| ATE33761T1 (de) | Komplexe von prostaglandinen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |